ASH 2024 Summary: Highlights in AML, MDS, and ALL

2024 ASH Annual Meeting Insights Hub

T. Badar

ASH 2024 Summary: Highlights in Adult ALL and Implications for Pract…

2024 ASH Annual Meeting Insights Hub

R. Cassaday

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Recent Updates on Blinatumomab in ALL: FDA Approval in 1L and Incorp…

Sarah Tasian

AML and MDS Highlights & Key Takeaways

Insights from 2023 ASH Annual Meeting

T. Badar

ASH 2024 Insights: COG AALL1731 - Blinatumomab Added to Chemo in New…

2024 ASH Annual Meeting Insights Hub

S. Gupta

Updates in ALL: Incorporating Immunotherapy in Frontline Management

Talha Badar

ALL in Adults: Overview and Recent Advances

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

R. Cassaday

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Incorporation of Targeted and Immunotherapies in ALL

XV Eurasian Hematology-Oncology Congress - EHOC 2024

H. Kantarjian

MRD Testing in Leukemias: When Negativity Is a Positive Thing

i3 Health

N. S. Raje

Blinatumomab in First-Line ALL - Safety, Efficacy, and Experience

Salman Fazal

Incorporating Blinatumomab and Inotuzumab Into 1L ALL Treatment

MyCancerHaven

R. Vij, N. Short

Treating Adults With Newly Diagnosed ALL

MyCancerHaven

R. Vij, A. Patel

Axatilimab in cGVHD: Mechanism of Action and Comparison With Current…

Noah Merin

The Role of Axatilimab in Targeting CSF1R for Inflammation and Fibro…

Daniel Wolff

Blinatumomab for Ph- ALL in First MRD-Negative Remission: E1910 and …

Fred Hutchinson Cancer Center

R. Cassaday

Treating Adult B-ALL: CAR-T vs. Bispecifics vs. Monoclonals

Marlise R. Luskin

Chronic GvHD: Main Complications After ASCT

Steven Pavletic

Immunotherapies in Acute Leukemias: 2024 Update

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

C. Lai